slide 1

Back to the List of the Granted Patents                                                Click here to download AP2089 PDF

(11)    Patent No :    AP 2089   
(21)    Application No :    AP/P/2005/003348   
(22)    Filing Date :    13.01.2004   
(24)    Date of Grant &    11.01.2010   
(45)    Publication :

(30)  Priority Data       
(33) Country    (31) Number    (32) Date
US    60/440,308    14.01.2003
US    60/440,246    14.01.2003

(84)    Designated State

BW    GM  GH   KE   LS   MW  MZ   NA   SL

SD    SZ   T Z   UG   ZM   ZW

(73) Applicant(s)

GILEAD SCIENCES, INC., 333 Lakeside Drive, Foster City,

CA 94404,
United States of America
(72) Inventors

DAHL Terrence C, United States of America

MENNING Mark M, United States of America

OLIYAL Reza, United States of America

et al

(74) Representative


(51)  International  Classification   A61K 31/513 (2006.01)    A61K 31/675 (2006.01)
A61K 31/7076 (2006.01)   

(54)    Title

Compositions and methods for combination antiviral therapy

(57)    Abstract

The present invention relates to therapeutic combinations of

[2-(6-amino-purin-9 yl)-1-methyl-ethoxymethyl]-phosphonic acid diisopropoxycarbonyloxymethyl ester (tenofovir disoproxil fumarate, Viread®) and (2R, 5S, cis)-4-amino-5-fluoro-1-(2

hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (emtricitabine, EmtrivaTM, (-)-cis FTC) and their physiologically functional derivatives. The combinations may be useful in the treatment of HIV infections, including infections with HIV mutants bearing resistance to nucleoside and/or

non-nucleoside inhibitors. The present invention is also concerned with pharmaceutical compositions and formulations of said combinations of tenofovir disoproxil fumarate and emtricitabine, and their physiologically functional derivatives, as well as therapeutic methods of use of those compositions and formulations.

(56)    Documents Cited :    Journal of Infectious Diseases, 2002, 186: 1844-7    Journal of Virology, 12/01/2003, 77:

1120-30    WO 00 25797 A


Join our newsletter for CIPIT news through subscriptions!


Social Media


Contact Us

TEL : (254) 703 034 612